Scholarlink

<p><i>Pseudomonas aeruginosa</i> is a gram-negative clinical pathogen, particularly affecting immunocompromised patients, those with cystic fibrosis, and burn victims. It causes chronic infections, especially in hospital settings, and is a significant contributor to nosocomial infections. Its capacity to create biofilms resistant to antibiotics is the reason for its infamous persistence in clinical settings. <i>P. aeruginosa</i> infections can affect any area of the body because the bacteria’s biofilm enables it to stick to any surface, living or non-living. One of the primary clinical challenges in treating <i>P. aeruginosa</i> biofilm is its noteworthy resistance to many classes of antibiotics. The bacterium’s ability to acquire resistance through efflux pumps, beta-lactamase production, and genetic mutations complicates treatment options. Recently, multidrug- resistant (MDR) strains of <i>P. aeruginosa</i> are becoming increasingly prevalent, limiting the efficacy of traditional antibiotics and leading to the need for alternative therapies. There is an ongoing need for novel treatment options, including bacteriophage therapy, antimicrobial peptides, and vaccines. The rapid adaptability of <i>P. aeruginosa</i> and its ability to develop resistance underscores the importance of continued research into new therapeutic strategies. This review discusses the various therapeutic strategies like; antimicrobial therapy, targeting efflux pumps and biofilms of <i>P. aeruginosa</i>, phage therapy, immunotherapy and nanotechnology to explore the mechanisms, through which antimicrobial compounds interact with biofilm structures and the bacteria within.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Rajeshwari Lekhwar,
  • Sunil Kumar,
  • Mahima Tripathi,
  • Saurabh Gangola,
  • Anil Kumar Sharma

摘要

Pseudomonas aeruginosa is a gram-negative clinical pathogen, particularly affecting immunocompromised patients, those with cystic fibrosis, and burn victims. It causes chronic infections, especially in hospital settings, and is a significant contributor to nosocomial infections. Its capacity to create biofilms resistant to antibiotics is the reason for its infamous persistence in clinical settings. P. aeruginosa infections can affect any area of the body because the bacteria’s biofilm enables it to stick to any surface, living or non-living. One of the primary clinical challenges in treating P. aeruginosa biofilm is its noteworthy resistance to many classes of antibiotics. The bacterium’s ability to acquire resistance through efflux pumps, beta-lactamase production, and genetic mutations complicates treatment options. Recently, multidrug- resistant (MDR) strains of P. aeruginosa are becoming increasingly prevalent, limiting the efficacy of traditional antibiotics and leading to the need for alternative therapies. There is an ongoing need for novel treatment options, including bacteriophage therapy, antimicrobial peptides, and vaccines. The rapid adaptability of P. aeruginosa and its ability to develop resistance underscores the importance of continued research into new therapeutic strategies. This review discusses the various therapeutic strategies like; antimicrobial therapy, targeting efflux pumps and biofilms of P. aeruginosa, phage therapy, immunotherapy and nanotechnology to explore the mechanisms, through which antimicrobial compounds interact with biofilm structures and the bacteria within.